T-Therapeutics is developing ‘optimal’ TCR based therapeutics using its proprietary OpTiMus® platform, based on a fully humanized TCR mouse that provides an almost unlimited source of unique, antigen-specific human TCRs. Here are details of T-Therapeutics latest funding round :
🚀 Launch
2022
🏭 Industry
Biotechnology
🧠Management
Allan Bradley (CEO)
💸 Funding & Investors
| INVESTMENT (Novembre 2023) | £48 million (Series A) |
| INVESTORS (Novembre 2023) | led by Sofinnova Partners, F-Prime Capital, Digitalis Ventures and Cambridge Innovation Capital (CIC) with participation from Sanofi Ventures and the University of Cambridge Venture Fund. |
🎯 Funding purpose
Discover and develop novel T cell receptor (TCR) therapeutics for cancer indications as well as inflammatory disorders.
🌐 Country HQ
UK (Cambridge)